InterMune Bought

It has been a bizarre ride for InterMune, its employees, and its investors. But now it ends with Roche buying them for $8.3 billion dollars, a sum that would have brought incredulous stares a few years ago. The deal makes sense for Roche, and it will provide investors a rationale for years as they buy into small biopharma companies - trying to pick the next InterMune, you know.

Source: In the Pipeline - August 25, 2014 Category: Chemists Tags: Business and Markets Source Type: blogs